4DMedical Limited FDMDF
1.95 USD 0.00 (+0.00%)
At closeNov 3, 2026, 4:00 PM EST
2.40 Day range 2.40
0.8701 52-week range 5.00
- YTD
- -17.02%
- 1 year
- +74.11%
- Market cap
- 1.17B
- EPS (ttm)
- -0.26
- YTD return
- -17.02%
- 1-year return
- +74.11%
- Volume
- 100
- Avg volume
- 669
- Open
- 2.40
- Previous close
- 1.95
- Day's range
- 2.40 – 2.40
- 52-week range
- 0.8701 – 5.00
- Earnings date
- Aug 27, 2026
2Y +1.61 (+473.53%)
Next earnings
Aug 27, 2026
Expected Aug 27, 2026. Consensus EPS estimate -0.02799.
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Aug 27, 2026 | Jun 30, 2026 | -0.02799 | — | — | — |
| Feb 26, 2026 | Dec 31, 2025 | -0.02415 | -0.17282 | -0.15 | -615.61% |
| Aug 28, 2025 | Jun 30, 2025 | — | -0.03102 | — | — |
| Feb 26, 2025 | Dec 31, 2024 | -0.02475 | -0.01919 | +0.01 | +22.46% |
| Sep 29, 2024 | Jun 30, 2024 | — | -0.04534 | — | — |
| May 9, 2024 | Dec 31, 2023 | — | -0.02859 | — | — |
News
4DMedical Limited (FDMDF) Shareholder/Analyst Call Transcript 
4DMedical Limited (FDMDF) M&A Call Transcript 
4DMedical Limited (FDMDF) Discusses Clinical Use of CT:VQ in Patient Selection for Lung Volume Reduction Surgery Transcript 
4DMedical receives CE Mark for CT:VQ™, enabling commercial launch across the European Union 
4DMedical Secures US$100+ Million Funding to Accelerate U.S. Expansion and increase Technology Dominance in Software-Based Lung Imaging 
4DMedical Limited (FDMDF) Discusses Imaging Technology Portfolio and Market Positioning in Cardio-Pulmonary Diagnostics Transcript 
4DMedical Limited (FDMDF) Discusses Expansion of Distribution Agreement for CT:VQ Non-Contrast Lung Imaging Solution Transcript 
4DMedical Limited - Special Call 
4DMedical's CT:VQ™ receives FDA 510(k) clearance; First-and-only CT-based VQ technology
Your note
Sign in to keep a note on FDMDF — it syncs with the Stock Master app.